Natural killer cells in antitumour adoptive cell immunotherapy
TJ Laskowski, A Biederstädt, K Rezvani - Nature Reviews Cancer, 2022 - nature.com
Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with
intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing …
intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing …
CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
CAR-T cell therapy: current limitations and potential strategies
RC Sterner, RM Sterner - Blood cancer journal, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
Co-opting signalling molecules enables logic-gated control of CAR T cells
AM Tousley, MC Rotiroti, L Labanieh, LW Rysavy… - Nature, 2023 - nature.com
Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
CAR T cells in solid tumors: challenges and opportunities
F Marofi, R Motavalli, VA Safonov… - Stem cell research & …, 2021 - Springer
Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent pembrolizumab
PS Adusumilli, MG Zauderer, I Rivière, SB Solomon… - Cancer discovery, 2021 - AACR
Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant
pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response …
pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response …